SCHEMBL2669971

SCHEMBL2669971

CC(C)Oc1cc(Oc2ccc(S(C)(=O)=O)cc2)cc(C(=O)Nc2nc(-c3ccc(P(=O)(O)O)cc3)cs2)c1

nearest known ligand 0.71

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
▸ GCK P35557 19/20 0.71
▸ KDM4E B2RXH2 1/20 0.58
▸ RAB9A P51151 1/20 0.58
▸ KCNH2 Q12809 2/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9982925 0.87 GCK (0.71) GCKKCNH2
SCHEMBL12021702 0.85 GCK (0.69) GCKKCNH2
SCHEMBL12021329 0.85 GCK (0.62) GCKKCNH2
SCHEMBL3602195 0.83 GCK (1.00) GCKRAB9AKCNH2
SCHEMBL18707629 0.83 GCK (0.62) GCKKDM4ERAB9AKCNH2
SCHEMBL12021247 0.82 GCK (0.75) GCKRAB9A
SCHEMBL13255097 0.82 GCK (0.80) GCKKCNH2
SCHEMBL3605901 0.82 GCK (0.80) GCKKCNH2
SCHEMBL3596787 0.81 GCK (0.78) GCKKCNH2
SCHEMBL13282946 0.81 GCK (0.78) GCKKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10174062-B2 Activators of glucokinase METABASIS THERAPEUTICS, INC. (US) 2019-01-08 — — US disclosed
US-10005805-B2 — — 2018-06-26 — — US disclosed
US-10005805-B2 — — 2018-06-26 — — US disclosed
US-20170096440-A1 NOVEL ACTIVATORS OF GLUCOKINASE METABASIS THERAPEUTICS, INC. 2017-04-06 — — US disclosed
US-20170096440-A1 NOVEL ACTIVATORS OF GLUCOKINASE METABASIS THERAPEUTICS, INC. 2017-04-06 — — US disclosed
US-9522926-B2 Activators of glucokinase METABASIS THERAPEUTICS, INC. (US) 2016-12-20 — — US disclosed
US-9522926-B2 Activators of glucokinase METABASIS THERAPEUTICS, INC. (US) 2016-12-20 — — US disclosed
US-20150119365-A1 NOVEL ACTIVATORS OF GLUCOKINASE CITIBANK, N.A., AS ADMINISTRATIVE AGENT 2015-04-30 — — US disclosed
US-20150119365-A1 NOVEL ACTIVATORS OF GLUCOKINASE CITIBANK, N.A., AS ADMINISTRATIVE AGENT 2015-04-30 — — US disclosed
US-8940927-B2 Activators of glucokinase METABASIS THERAPEUTICS, INC. (US) 2015-01-27 — — US disclosed
US-8940927-B2 Activators of glucokinase METABASIS THERAPEUTICS, INC. (US) 2015-01-27 — — US disclosed
US-20110294758-A1 NOVEL ACTIVATORS OF GLUCOKINASE METABASIS THERAPEUTICS, INC. (US) 2011-12-01 — — US disclosed
US-20110294758-A1 NOVEL ACTIVATORS OF GLUCOKINASE METABASIS THERAPEUTICS, INC. (US) 2011-12-01 — — US disclosed
WO-2009023718-A2 NOVEL ACTIVATORS OF GLUCOKINASE METABASIS THERAPEUTICS, INC. (US) 2009-02-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10005805-B2 — GCKR, GCK, HK1 GCK 2/4885KDM4E 4072/4885RAB9A 2395/4885
US-20150119365-A1 NOVEL ACTIVATORS OF GLUCOKINASE GCKR, GCK, HK1 GCK 2/4885KDM4E 3996/4885RAB9A 2391/4885
US-20110294758-A1 NOVEL ACTIVATORS OF GLUCOKINASE GCKR, GCK, HK1 GCK 2/4885KDM4E 3996/4885RAB9A 2391/4885
US-20170096440-A1 NOVEL ACTIVATORS OF GLUCOKINASE GCKR, GCK, HK1 GCK 2/4885KDM4E 3996/4885RAB9A 2391/4885
US-10174062-B2 Activators of glucokinase GCKR, GCK, HK1 GCK 2/4885KDM4E 4021/4885RAB9A 2523/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback